NOVAVAX INC — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Novavax reported Q2 2026 total revenue of $57M (down 76% YoY from $239M, due to $202M in one-time milestones in Q2 2025). The company raised FY2026 Adjusted Total Revenue guidance to $235–$275M and improved Combined R&D + SG&A expense guidance by ~$10M midpoint to $370–$410M. Key upcoming milestones: Sanofi Phase 3 COVID-19-Influenza trial initiation would trigger $125M payment; manufacturing tech transfer completion (mid-2027) would trigger $75M payment. Cash position: $724M as of June 30, 2026.
Why this rating
Revenue decline is largely YoY comp noise (prior year had large milestones); core adjusted guidance improvement modest (≈1% of company value). Sanofi partnership is material but contingent on regulatory/execution milestones, not yet realized. Moderate operational progress, not transformational.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.